DK2968267T3 - Bløde anticholinerge estere til behandling af hyperhidrose - Google Patents
Bløde anticholinerge estere til behandling af hyperhidrose Download PDFInfo
- Publication number
- DK2968267T3 DK2968267T3 DK14720386.3T DK14720386T DK2968267T3 DK 2968267 T3 DK2968267 T3 DK 2968267T3 DK 14720386 T DK14720386 T DK 14720386T DK 2968267 T3 DK2968267 T3 DK 2968267T3
- Authority
- DK
- Denmark
- Prior art keywords
- composition
- cyclopentyl
- phenyl
- hydroxyacetoxy
- approx
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Claims (14)
1. Sammensætning, der omfatter (i) fra ca. 1,0 % til ca. 25 % af en forbindelse med formlen (I):
hvor R er methyl eller ethyl, hvor forbindelsen har R-stereoisomer konfiguration ved 2-positionen og R-, S- eller RS-stereoisomer konfiguration ved Γ- og 3’-positionen, eller er en blanding deraf; og (ii) et farmaceutisk acceptabelt vehikel, til anvendelse i behandlingen af hyperhidrose, hvor sammensætningen er beregnet til at blive administreret topisk på et individs angrebne hudområde.
2. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen er beregnet til at blive administreret én gang dagligt.
3. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen har en forbedret sikkerhedsprofil sammenlignet med topisk glycopyrrolat.
4. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen omfatter ca. 2,0 % til ca. 25 % af komponenten.
5. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen er beregnet til topisk påføring på et hudområde af individet inden ca. 1-2 timer før individets søvnperiode, hvorved, sammenlignet med ubehandlede baselinetilstande, svedproduktion reduceres med mindst ca. 25 % i mindst ca. seks (6) timer efter administration af sammensætningen, og hvor svedproduktion reduceres med en mængde i det væsentlige svarende til en mængde, som svedproduktion reduceres med sammenlignet med ubehandlede baselinetilstande, efter administration af en sammensætning, der omfatter en ækvivalent koncentration af glycopyrrolat.
6. Sammensætning til anvendelse ifølge krav 5, hvor én eller flere af følgende egenskaber gør sig gældende: a) individet er et menneske; b) svedproduktion reduceres med ca. 25 % til ca. 99 %; c) sammensætningen er formuleret som et fast eller halvfast stof, et pulver, en gel, creme, lotion, et skum, en opløsning, suspension eller emulsion; d) svedproduktion reduceres med ca. 8 timer til ca. 24 timer; e) R er methyl; f) sammensætningen er beregnet til at blive påført individets hud i et anatomisk overfladeområde udvalgt fra et håndfladeområde, et fodsålsområde, et lyskeområde, et armhuleområde eller et ansigtsområde.
7. Sammensætning til anvendelse ifølge krav 5 eller 6, hvor én eller flere af følgende egenskaber gør sig gældende: a) svedproduktion reduceres med ca. 30 % til ca. 75 %; b) sammensætningen er formuleret som et fast eller halvfast stof, et pulver, en gel, creme, lotion, et skum, en opløsning, suspension eller emulsion, der omfatter fra ca. 2 % til ca. 10 % af forbindelsen; c) svedproduktion reduceres med ca. 8 timer til ca. 12 timer; d) R er ethyl.
8. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 7, hvor én eller flere af følgende egenskaber gør sig gældende: a) svedproduktion reduceres med ca. 45 % til ca. 60 %; b) sammensætningen er formuleret som en 5 % opløsning af forbindelsen i 70 % ethanol.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 8, hvor svedproduktion reduceres med ca. 50 %.
10. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 9, hvor en anden dosis af sammensætningen skal administreres efter individets søvncyklus, hvor administrationen af den anden dosis ligger inden ca. 6 til 10 timer fra den initiale administration inden ca. 1-2 timer før individets søvnperiode.
11. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor forbindelsen er udvalgt fra gruppen bestående af: (i) (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (ii) (2R) 3 -(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (iii) (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (iv) (2R,3’S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (v) (2R,3’R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacctoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (vi) (2R,3’S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (vii) (2R, 1 'R,3’S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (viii) (2R,1'S,3’S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (ix) (2R, 1 ’R,3 ’R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (x) (2R,1’S,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (xi) (2R, 1 ’R,3'S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (xii) (2R, 1 ’S,3'S) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid; (xiii) (2R, 1 'R,3 ’R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l -(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid og (xiv) (2R, 1 'S,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1 -(methoxycarbonylmethyl)-1 -methylpyrrolidiniumbromid.
12. Sammensætning til anvendelse ifølge krav 11, hvor forbindelsen er udvalgt fra gruppen bestående af: (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-l-methylpyrrolidiniumbromid; (2R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-l-methylpyrrolidiniumbromid; (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1 -(methoxycarbonylmethyl)-l-methylpyrrolidiniumbromid og (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1 -(ethoxycarbonylmethyl)-l-methylpyrrolidiniumbromid.
13. Sammensætning til anvendelse ifølge krav 12, hvor forbindelsen er: (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(methoxycarbonylmethyl)-l-methylpyrrolidiniumbromid.
14. Sammensætning til anvendelse ifølge krav 12, hvor forbindelsen er: (2R,3'R) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-l-(ethoxycarbonylmethyl)-l-methylpyrrolidiniumbromid.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798073P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028332 WO2014144075A1 (en) | 2013-03-15 | 2014-03-14 | Anticholinergic glycopyrrolate esters for the treatment of hyperhidrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2968267T3 true DK2968267T3 (da) | 2018-06-25 |
Family
ID=50625156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14720386.3T DK2968267T3 (da) | 2013-03-15 | 2014-03-14 | Bløde anticholinerge estere til behandling af hyperhidrose |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US9220707B2 (da) |
| EP (1) | EP2968267B1 (da) |
| JP (4) | JP6223543B2 (da) |
| KR (4) | KR102153457B1 (da) |
| CN (2) | CN109364066A (da) |
| AU (1) | AU2014227923B2 (da) |
| BR (1) | BR112015023153A2 (da) |
| CA (1) | CA2904724C (da) |
| DK (1) | DK2968267T3 (da) |
| ES (1) | ES2673098T3 (da) |
| HK (2) | HK1217177A1 (da) |
| HU (1) | HUE038448T2 (da) |
| IL (1) | IL241307B (da) |
| MX (1) | MX363601B (da) |
| MY (1) | MY192033A (da) |
| PH (1) | PH12015501987A1 (da) |
| PL (1) | PL2968267T3 (da) |
| PT (1) | PT2968267T (da) |
| SG (1) | SG11201507602SA (da) |
| TR (1) | TR201808040T4 (da) |
| WO (1) | WO2014144075A1 (da) |
| ZA (1) | ZA201506834B (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201808040T4 (tr) * | 2013-03-15 | 2018-06-21 | Bodor Laboratories Inc | Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler. |
| US20150259283A1 (en) | 2014-03-13 | 2015-09-17 | Brickell Biotech, Inc. | Formulation for soft anticholinergic analogs |
| WO2015138700A1 (en) | 2014-03-13 | 2015-09-17 | Bodor Laboratories, Inc. | Use of selected anticholinergic zwitterions |
| WO2016175240A1 (ja) * | 2015-04-30 | 2016-11-03 | 久光製薬株式会社 | 多汗症治療用外用剤 |
| EP3325487B1 (en) * | 2015-07-21 | 2021-05-05 | Bodor Laboratories, Inc. | Formulation for soft anticholinergic analogs |
| AU2016318594A1 (en) * | 2015-09-11 | 2018-04-26 | Bodor Laboratories, Inc. | Methods and compositions for soft anticholinergic zwitterions |
| US11534422B2 (en) * | 2015-09-11 | 2022-12-27 | Bodor Laboratories, Inc. | Methods and compositions for soft anticholinergic esters |
| WO2018006001A1 (en) * | 2016-07-01 | 2018-01-04 | Bodor Laboratories, Inc. | Compositions and methods for treatment of copd |
| TWI767507B (zh) | 2016-07-21 | 2022-06-11 | 美商波德實驗股份有限公司 | 軟性抗膽鹼類似物之製劑 |
| KR101951021B1 (ko) | 2017-02-06 | 2019-02-22 | 주식회사 퍼슨 | 발한억제 기능을 가지는 자외선 차단 화장료 조성물 및 이를 사용한 자외선 차단제의 제조방법 |
| ES2761325T3 (es) * | 2017-07-17 | 2020-05-19 | Dr August Wolff Gmbh & Co Kg Arzneimittel | Emulsión de aceite en agua |
| WO2020020879A1 (en) | 2018-07-24 | 2020-01-30 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical emulsion of an anticholinergic compound |
| SG10201912063PA (en) * | 2019-12-12 | 2021-07-29 | Nat Skin Centre Singapore Pte Ltd | A pharmaceutical formulation |
| KR20220149551A (ko) | 2020-03-03 | 2022-11-08 | 가켄 세이야쿠 가부시키가이샤 | 원발성 겨드랑이 다한증의 치료방법 및 그의 의약 |
| CN115175665B (zh) | 2020-03-03 | 2024-04-16 | 科研制药株式会社 | 含有索吡溴铵的药物 |
| WO2023198876A1 (en) | 2022-04-14 | 2023-10-19 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
| EP4260852A1 (en) | 2022-04-14 | 2023-10-18 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical formulation of an anticholinergic compound for treating severe hyperhidrosis and excessive sweating |
| KR102611847B1 (ko) * | 2023-03-27 | 2023-12-12 | 주식회사 이플라스크 | 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292530A (en) | 1991-06-02 | 1994-03-08 | Helene Curtis, Inc. | Stable anhydrous topically-active composition and suspending agent therefor |
| CA2461696A1 (en) | 2001-09-26 | 2003-04-03 | Alison B. Lukacsko | Compositions and methods for inhibiting eccrine perspiration in humans |
| US8252316B2 (en) | 2002-05-03 | 2012-08-28 | Purepharm Inc. | Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating |
| GB0428418D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| GB0428416D0 (en) | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| JP5257073B2 (ja) * | 2005-11-10 | 2013-08-07 | ボーダー、ニコラス・エス | ソフト型抗コリン作動性エステル |
| US7399861B2 (en) | 2005-11-10 | 2008-07-15 | Bodor Nicholas S | Soft anticholinergic esters |
| US8071693B2 (en) | 2006-06-22 | 2011-12-06 | Sabic Innovative Plastics Ip B.V. | Polysiloxane/polyimide copolymers and blends thereof |
| WO2009051818A1 (en) | 2007-10-18 | 2009-04-23 | Stiefel Research Australia Pty Ltd | Topical glycopyrrolate formulations |
| TR201808040T4 (tr) * | 2013-03-15 | 2018-06-21 | Bodor Laboratories Inc | Hiperhidrozun tedavisine yönelik yumuşak antikolinerjik esterler. |
-
2014
- 2014-03-14 TR TR2018/08040T patent/TR201808040T4/tr unknown
- 2014-03-14 DK DK14720386.3T patent/DK2968267T3/da active
- 2014-03-14 KR KR1020197034502A patent/KR102153457B1/ko active IP Right Grant
- 2014-03-14 WO PCT/US2014/028332 patent/WO2014144075A1/en active Application Filing
- 2014-03-14 MY MYPI2015702984A patent/MY192033A/en unknown
- 2014-03-14 BR BR112015023153A patent/BR112015023153A2/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020217010876A patent/KR20210043742A/ko not_active Application Discontinuation
- 2014-03-14 AU AU2014227923A patent/AU2014227923B2/en active Active
- 2014-03-14 CN CN201811323473.XA patent/CN109364066A/zh active Pending
- 2014-03-14 MX MX2015012072A patent/MX363601B/es unknown
- 2014-03-14 US US14/213,242 patent/US9220707B2/en active Active
- 2014-03-14 SG SG11201507602SA patent/SG11201507602SA/en unknown
- 2014-03-14 ES ES14720386.3T patent/ES2673098T3/es active Active
- 2014-03-14 CN CN201480015677.0A patent/CN105050596A/zh active Pending
- 2014-03-14 PL PL14720386T patent/PL2968267T3/pl unknown
- 2014-03-14 HU HUE14720386A patent/HUE038448T2/hu unknown
- 2014-03-14 PT PT147203863T patent/PT2968267T/pt unknown
- 2014-03-14 KR KR1020207015539A patent/KR102241660B1/ko active IP Right Grant
- 2014-03-14 CA CA2904724A patent/CA2904724C/en active Active
- 2014-03-14 KR KR1020157028470A patent/KR102050299B1/ko active IP Right Grant
- 2014-03-14 EP EP14720386.3A patent/EP2968267B1/en active Active
- 2014-03-14 JP JP2016502761A patent/JP6223543B2/ja active Active
-
2015
- 2015-09-07 PH PH12015501987A patent/PH12015501987A1/en unknown
- 2015-09-08 IL IL241307A patent/IL241307B/en active IP Right Grant
- 2015-09-15 ZA ZA2015/06834A patent/ZA201506834B/en unknown
- 2015-11-13 US US14/941,183 patent/US9492429B2/en active Active
-
2016
- 2016-05-06 HK HK16105192.7A patent/HK1217177A1/zh unknown
- 2016-07-01 US US15/200,129 patent/US9895350B2/en active Active
- 2016-07-18 HK HK16108429.6A patent/HK1220369A1/zh unknown
-
2017
- 2017-02-03 JP JP2017018832A patent/JP6461214B2/ja active Active
-
2018
- 2018-02-16 US US15/932,334 patent/US10383846B2/en active Active
- 2018-03-22 JP JP2018054386A patent/JP6694908B2/ja active Active
-
2019
- 2019-07-02 US US16/460,252 patent/US10772867B2/en active Active
-
2020
- 2020-04-20 JP JP2020074670A patent/JP7008988B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10772867B2 (en) | Method of dosing and use of soft anticholinergic esters | |
| AU2019257421B2 (en) | Formulation for soft anticholinergic analogs |